Improving the Primary Prevention of Cardiovascular Events by Using Biomarkers to Identify Individuals With Silent Heart Disease

被引:77
作者
Nadir, M. Adnan [1 ]
Rekhraj, Sushma [1 ]
Wei, Li [2 ]
Lim, Tiong K. [1 ]
Davidson, John [3 ]
MacDonald, Thomas M. [2 ]
Lang, Chim C. [1 ]
Dow, Ellie [4 ]
Struthers, Allan D. [1 ]
机构
[1] Univ Dundee, Ctr Cardiovasc & Lung Biol, Dundee DD1 9SY, Scotland
[2] Univ Dundee, Med Monitoring Unit, Dundee DD1 9SY, Scotland
[3] Ninewells Hosp, Dept Nucl Med, Dundee DD1 9SY, Scotland
[4] Natl Hlth Serv, Dept Biochem Med, Dundee, Scotland
关键词
biomarkers; cardiovascular risk; primary prevention; LEFT-VENTRICULAR HYPERTROPHY; PROSTATE-SPECIFIC ANTIGEN; NATRIURETIC PEPTIDE; MYOCARDIAL-ISCHEMIA; OF-ECHOCARDIOGRAPHY; DIABETIC-PATIENTS; RISK; DYSFUNCTION; FAILURE; RECOMMENDATIONS;
D O I
10.1016/j.jacc.2012.04.049
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The aim of this study was to examine whether biomarkers can identify silent cardiac target organ damage (cTOD) in a primary prevention population. Background One possible way to improve primary prevention of cardiovascular events is to identify those patients who already harbor silent cTOD (i.e., myocardial ischemia, left ventricular hypertrophy, systolic dysfunction, diastolic dysfunction, or left atrial enlargement). This might be possible by screening with a biomarker (e.g. high sensitivity cardiac troponin T [hs-cTnT] or B-type natriuretic peptide [BNP]). Methods We prospectively recruited 300 asymptomatic individuals already receiving primary prevention therapy. Transthoracic echocardiography, stress echocardiography, and/or myocardial perfusion imaging were performed to identify silent cTOD. Results One hundred two (34%) patients had evidence of cTOD. Left ventricular hypertrophy was the most prevalent (29.7%) form of cTOD, followed by diastolic dysfunction (21.3%), left atrial enlargement (15.3%), systolic dysfunction (6.3%), and ischemia (6.3%). The area under the curve (AUC) for BNP to identify any form of silent cTOD was 0.78 overall and 0.82 in men. The equivalent figures for hs-cTnT were 0.70 and 0.75 in women. The AUC for BNP and hs-cTnT together was 0.81 and 0.82 in men. However, the discrimination power of other markers was poor, with AUCs of 0.61 for microalbuminuria, 0.49 for uric acid, and 0.58 for eGFR. Conclusions In asymptomatic treated primary prevention patients, BNP screening is able to identify existing silent cTOD. The performance of hs-cTnT was not as good as that of BNP. B-type natriuretic peptide plus hs-cTnT together performed best. Prescreening with BNP +/- cTnT followed by targeted phenotyping is worth exploring further as a possible way to improve primary prevention. (J Am Coll Cardiol 2012;60:960-8) (C) 2012 by the American College of Cardiology Foundation
引用
收藏
页码:960 / 968
页数:9
相关论文
共 36 条
[1]   BSE procedure guidelines for the clinical application of stress echocardiography, recommendations for performance and interpretation of stress echocardiography - A report of the British Society of Echocardiography Policy Committee [J].
Becher, H ;
Chambers, J ;
Fox, K ;
Jones, R ;
Leech, GJ ;
Masani, N ;
Monaghan, M ;
More, R ;
Nihoyannopoulos, P ;
Rimington, H ;
Senior, R ;
Warton, G .
HEART, 2004, 90 :23-30
[2]   LEFT ATRIAL SIZE AND THE RISK OF STROKE AND DEATH - THE FRAMINGHAM HEART-STUDY [J].
BENJAMIN, EJ ;
DAGOSTINO, RB ;
BELANGER, AJ ;
WOLF, PA ;
LEVY, D .
CIRCULATION, 1995, 92 (04) :835-841
[3]   Can a Cardiac Peptide Predict Mortality in Human Hypertension? [J].
Cannone, Valentina ;
McKie, Paul M. ;
Burnett, John C., Jr. .
HYPERTENSION, 2011, 57 (04) :670-671
[4]   Healthy lifestyle factors in the primary prevention of coronary heart disease among men - Benefits among users and nonusers of lipid-lowering and antihypertensive medications [J].
Chiuve, Stephanie E. ;
McCullough, Marjorie L. ;
Sacks, Frank M. ;
Rimm, Eric B. .
CIRCULATION, 2006, 114 (02) :160-167
[5]  
Davie AP, 1996, BRIT MED J, V312, P222
[6]   B-type natriuretic peptide is associated with both augmentation index and left ventricular mass in diabetic patients without heart failure [J].
Dawson, A ;
Davies, JI ;
Morris, AD ;
Struthers, AD .
AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (12) :1586-1591
[7]   Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population [J].
de Lemos, James A. ;
Drazner, Mark H. ;
Omland, Torbjorn ;
Ayers, Colby R. ;
Khera, Amit ;
Rohatgi, Anand ;
Hashim, Ibrahim ;
Berry, Jarett D. ;
Das, Sandeep R. ;
Morrow, David A. ;
McGuire, Darren K. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 304 (22) :2503-2512
[8]   Out-of-hospital cardiac arrest in the 1990s: A population-based study in the Maastricht area on incidence, characteristics and survival [J].
deVreedeSwagemakers, JJM ;
Gorgels, APM ;
DuboisArbouw, WI ;
vanRee, JW ;
Daemen, MJAP ;
Houben, LGE ;
Wellens, HJJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1997, 30 (06) :1500-1505
[9]   Effects of anti-ischaemic drug therapy in silent myocardial ischaemia type I: the Swiss Interventional Study on Silent Ischaemia type I (SWISSI I): a randomized, controlled pilot study [J].
Erne, Paul ;
Schoenenberger, Andreas W. ;
Zuber, Michel ;
Burckhardt, Dieter ;
Kiowski, Wolfgang ;
Dubach, Paul ;
Resink, Therese ;
Pfisterer, Matthias .
EUROPEAN HEART JOURNAL, 2007, 28 (17) :2110-2117
[10]   Effects of percutaneous coronary interventions in silent ischemia after myocardial infarction - The SWISSI II randomized controlled trial [J].
Erne, Paul ;
Schoenenberger, Andreas W. ;
Burckhardt, Dieter ;
Zuber, Michel ;
Kiowski, Wolfgang ;
Buser, Peter T. ;
Dubach, Paul ;
Resink, Therese J. ;
Pfisterer, Matthias .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (18) :1985-1991